Table 1.
Clinical and demographic data of participants.
| Cohort | Diagnosis | n (M/F) | Age, y | p-Value | K-MMSE | p-Value | Amyloid PET |
|---|---|---|---|---|---|---|---|
| Microarray for miRNAs in plasma (Cohort 1) |
Control | 36 (16/20) | 72.86 ± 4.72 | - | 27.31 ± 2.69 | - | - |
| aMCI | 24 (12/12) | 74.22 ± 4.51 | 0.115 | 25.94 ± 2.54 | 0.018 | - | |
| AD | 36 (20/16) | 73.58 ± 5.72 | 0.344 | 17.34 ± 8.17 | 2.35 × 10−9 | - | |
| qPCR for miRNAs in plasma (Cohort 2) |
Control | 31 (18/13) | 72.85 ± 5.31 | - | 27.10 ± 1.83 | negative | |
| PSAD | 12 (6/6) | 73.99 ± 3.32 | 0.247 | 26.67 ± 3.55 | 0.28 | positive | |
| PDAD | 20 (10/10) | 74.38 ± 4.80 | 0.150 | 25.35 ± 3.69 | 1.45 × 10−2 | positive | |
| AD | 20 (8/12) | 72.54 ± 3.61 | 0.411 | 17.50 ± 4.83 | 8.67 × 10−14 | positive | |
| qPCR for miRNAs in CSF (Cohort 3) |
Control | 13 (7/6) | 74.46 ± 4.66 | 26.62 ± 1.56 | negative | ||
| PSAD | 10 (5/5) | 73.75 ± 4.24 | 0.373 | 26.90 ± 3.28 | 0.393 | positive | |
| PDAD | 13 (7/6) | 74.08 ± 5.87 | 0.428 | 25.46 ± 4.03 | 0.173 | positive | |
| AD | 14 (7/7) | 70.39 ± 4.82 | 0.017 | 17.93 ± 4.91 | 1.13 × 10−6 | positive |